Figure 6.
SOCS5 alleviates EAE symptoms by inhibiting pro-inflammatory response of Th17 cells through the JAKs/STAT3 pathway. (A) Clinical scores of EAE mice with different treatment; (B) Levels of JAKs/STAT3 pathway-related proteins and their phosphorylation levels in EAE mice detected by western blot analysis; vs. the blank group, ***p < 0.001; compared with the EAE group, #p < 0.05, ##p < 0.01, ###p < 0.001; (C,D) Detection of Treg and Th17 cells in spinal cord cells and splenocytes by flow cytometry; compared with the EAE group, *p < 0.05, **p < 0.01, ***p < 0.001; (E) Detection of inflammatory factors in spinal cord cells by ELISA; compared with the EAE group, *p < 0.05, **p < 0.01, ***p < 0.001. Data are analyzed with two-way ANOVA, and Tukey's multiple comparisons test was utilized for post hoc test n = 6.